PIB. Next Generation Direct-Acting Antivirals. Collectively: G/P. Pibrentasvir (formerly ABT-530) pangenotypic NS5A inhibitor

Size: px
Start display at page:

Download "PIB. Next Generation Direct-Acting Antivirals. Collectively: G/P. Pibrentasvir (formerly ABT-530) pangenotypic NS5A inhibitor"

Transcription

1 Surveyor-II, Part 3: Efficacy and Safety of Glecaprevir/Pibrentasvir (Abt-493/Abt-53) in Patients with Hepatitis C Virus Genotype 3 Infection with Prior Treatment Experience and/or Cirrhosis David L. Wyles, Fred Poordad, Stanley Wang, Laurent Alric, Franco Felizarta, Paul Y. Kwo, Benedict Maliakkal, Kosh Agar- wal, Tarek I. Hassanein, Frank Weilert, Samuel S. Lee, Ran Liu, Chih-Wei Lin, Teresa Ng, Federico Mensa Abstract 3 Next Generation Direct-Acting Antivirals Glecaprevir (formerly ABT-493) PIB pangenotypic NS3/4A protease inhibitor Pibrentasvir (formerly ABT-53) pangenotypic NS5A inhibitor Collectively: In vitro:, Clinical PK & metabolism: High barrier to resistance Potent against common NS3 polymorphisms (eg, positions 8, 55, and 68) and NS5A polymorphisms (eg, positions 8, 3, 3 and 93) Additive/synergistic antiviral activity Once-daily oral dosing Minimal metabolism and primary biliary excretion Negligible renal excretion (<%) is coformulated and dosed once daily as three mg/4 mg pills for a total dose of 3 mg/ mg Glecaprevir was identified by AbbVie and Enanta. Ng TI, et al. Abstract 636. CROI, 4.. Ng TI, et al. Abstract 639. CROI, 4.. Wyles D, et al. 67th AASLD; Boston, MA; November -5, 6; Abst. 3.

2 SURVEYOR-II Part 3: Study Design and Patient Population : Randomized Treatment Period TE without cirrhosis TE without cirrhosis N = 4 TN with cirrhosis N = 47 TE with cirrhosis Post-Treatment Period SVR SVR SVR SVR Weeks Included GT3 Patients without cirrhosis or with compensated cirrhosis Excluded prior treatment with HCV DAA other than SOF Excluded HBV or HIV coinfection Wyles D, et al. 67th AASLD; Boston, MA; November -5, 6; Abst. 3. Baseline Demographics and Clinical Characteristics Characteristic : Randomized Treatment Experienced Treatment Experienced Cirrhosis Cirrhosis Weeks 6 Weeks Treatment Naïve Cirrhosis Weeks N = 4 Treatment Experienced Cirrhosis 6 Weeks N = 47 Male, n (%) 4 (64) 4 (64) 4 (6) 36 (77) White race, n (%) 7 (77) (9) 37 (93) 4 (89) Age, median years (range) 56 (35 68) 59 (9 66) 56 (36 7) 59 (47 7) BMI, median kg/m (range) 6 (9 4) 8 ( 48) 9 ( 5) 7 ( 4) IL8B non-cc genotype, n (%) 5 (68) 9 (86) (5) 34 (7) HCV RNA, median log IU/mL (range) 6.6 (5. 7.5) 6. ( ) 6. (4. 7.) 6.5 (4.6 7.) HCV RNA 6,, IU/mL, n (%) 9 (4) 7 (3) 4 () () Prior treatment history, n (%) Naïve 4 () IFN/pegIFN ± RBV 4 (64) 3 (59) (47) SOF RBV ± pegifn 8 (36) 9 (4) 5 (53) Baseline Fibrosis Stage*, n (%) F-F (5) 5 (68) F 4 (8) (9) F3 7 (3) 5 (3) F4 4 () 47 () BMI, body mass index;, coformulated glecaprevir and pibrentasvir; HCV, hepatitis C virus; IFN, interferon; IL8B, interleukin 8; NS, non-structural protein; pegifn, pegylated interferon; SOF, sofosbuvir *Data missing for patient in Arm A (column ) and patient in Arm B (column 3) Wyles D, et al. 67th AASLD; Boston, MA; November -5, 6; Abst. 3.

3 Baseline Polymorphisms Baseline Polymorphism, n (%) Treatment Experienced Cirrhosis Weeks Treatment Experienced Cirrhosis 6 Weeks N = Treatment Naïve Cirrhosis Weeks N = 39 Treatment Experienced Cirrhosis 6 Weeks N = 47 6 (73) 8 (86) 9 (74) 4 (85) NS3 only (3) () NS5A only 6 (7) 3 (4) 9 (3) 6 (3) Both NS3 and NS5A *Baseline polymorphisms detected at 5% next-generation sequencing threshold only within samples that had sequences available for both targets at key amino acid positions: NS3: 55, 56, 68 NS5A: 4, 8, 3, 3, 58, 9, 93 Wyles D, et al. 67th AASLD; Boston, MA; November -5, 6; Abst. 3. SURVEYOR-II, Part 3: SVR Weeks Cirrhosis T-Experience Breakthrough LTFU SVR, % Patients 9 - : Randomized GT GT4 GT5 GT % of patients had HCV RNA <LLOQ by treatment week 4 Wyles D, et al. 67th AASLD; Boston, MA; November -5, 6; Abst. 3.

4 Virologic Failure: Patient Details Characteristic SURVEYOR-II Treatment Virologic Failure Compensated Cirrhosis Prior Treatment Experience Fibrosis Stage Baseline HCV RNA, IU/mL Treatment Compliance Patient A weeks No F-F 8,4, Patient B weeks No F 9,4, Patient C 6 weeks No F-F 8,9, Patient D 6 weeks F4,84, Patient E 6 weeks BT F4 7,4, NA* Sequence Analysis Baseline NS3 Failure Patient A Patient B Patient C Patient D Patient E A66S Y56H, Q68R A56G, A66S Baseline Y93H A3K A3K Failure Y93H A3K, Y93H A3K, Y93H L3F, Y93H A3K, Y93H NS5A BT, breakthrough NA, not available; *Patient E had drug exposures 85% lower than average at week 4 Substitutions detected by next-generation sequencing at 5% detection threshold NS3: 36, 43, 54, 55, 56, 8, 55, 56, 66, and 68 NS5A: 4, 8, 9, 3, 3, 3, 58, 9, and 93 Wyles D, et al. 67th AASLD; Boston, MA; November -5, 6; Abst. 3. SURVEYOR-II, Part 4: Glecaprevir/Pibrentasvir Demonstrates High SVR Rates in Patients with HCV Genotype, 4, 5, or 6 Infection without Cirrhosis Following an 8-Week Treatment Duration T.I. Hassanein, D.L. Wyles, S. Wang, R. Liu, T. Ng, C. Lin, F.J. Mensa, P.Y. Kwo, M.L. Shiffman, Z. Younes, S. Greenbloom, C.A. Stedman, J. Sasadeusz, H.I. Aguilar, J. Heo, Abstract LB-5

5 SURVEYOR-II, Part 4: Study Design SVR Assessment GT, 4, 5, 6 N =3 3 mg/ mg * Day Wk 8 Wk Wk 4 Open-label Treatment *Three mg/4 mg pills taken once daily. Hassanein T, et al. 67th AASLD; Boston, MA; November -5, 6; Abst. LB-5. SURVEYOR-II, Part 4: Results - SVR, ITT Population % Patients with SVR Breakthrough Discontinuation Missing SVR Data : : : 3: 4 45 * Overall GT GT4 GT5 GT6 9 Dotted line (yellow) represents the non-inferiority threshold (89%) *Patient discontinued on Day 5 due to loss to follow-up. Patient discontinued on Day 36 due to non-compliance. Hassanein T, et al. 67th AASLD; Boston, MA; November -5, 6; Abst. LB-5.

6 SURVEYOR-II, Part 4: Characteristics of Patients with Virologic Failure Time of Failure Patient A* Patient B post-treatment Day 9, post-treatment Day 55 Age/Race/Gender 56-year-old white female 55-year-old white male Genotype/Subtype GTa GTa C/C C/T IL8B Genotype Fibrosis Stage F F F3 5 IU/mL 7 IU/mL Experienced Experienced Treatment Compliant Compliantƚ NS3 NS5A Baseline Viral Load Prior Treatment Exposure Treatment Treatment-emergent substitutions at time of failure *Patient had a medical history of gastric bypass. Exposure of GLE on Day and Week 4 was >75% lower than the men in patients in the same treatment arm; exposure of PIB was comparable to the other patients in the cohort. ƚ Measured as the percentage of tables taken relative to the total tablets expected to be taken during the treatment period; compliance achieved if percentage was 8%. Hassanein T, et al. 67th AASLD; Boston, MA; November -5, 6; Abst. LB-5. EXPEDITION-IV: Safety and Efficacy of GLE/PIB in Adults with Renal Impairment and Chronic Hepatitis C Virus Genotype 6 Infection D. Pugatch, Y. Lei, M.P. Kosloski, F.J. Mensa, E. Lawitz, E.J. Gane, G.V. Papatheodoridis, N. Bräu, James J. Peters, A.S. Brown, S. Pol, V. Leroy, M. Persico, C. Moreno, M. Colombo, E.M. Yoshida, D.R. Nelson, G.V. Papatheodoridis, N. Bräu Abstract LB-

7 EXPEDITION-IV: Safety and Efficacy of GLE/PIB in Adults with Renal Impairment and Chronic Hepatitis C Virus Genotype 6 Infection EXPEDITION-4: Objective and Study Design GT 6 Stage 4/5 CKD /- cirrhosis TN or TE Treatment Period N = 4 Post-Treatment Period SVR Weeks Objective Determine the efficacy and safety of pangenotypic for weeks in patients with HCV GT-6 and stage 4 or 5 chronic kidney disease (CKD) Endpoints Efficacy: SVR defined as HCV RNA below the lower limit of quantification (LLOQ; 5 IU/mL) Safety: Adverse events (AEs) and laboratory abnormalities is coformulated and dosed once daily as three mg/4 mg pills for a total dose of 3 mg/ mg Gane E, et al. 67th AASLD; Boston, MA; November -5, 6; Abst. LB-. EXPEDITION-IV: Baseline Characteristics Characteristic N = 4 Male, n (%) 79 (76) Black race, n (%) 6 (5) Age, median years (range) 57 (8 83) BMI, median kg/m (range) 6 (8 45) IL8B non-cc genotype, n (%) 8 (77) HCV RNA, median log IU/mL (range) 5.9 ( ) Concomitant PPI use, n (%) 43 (4) Patients were enrolled across 9 countries: Australia, Belgium, Canada, France, Greece, Italy, New Zealand, the United Kingdom, and United States BMI, body mass index; CrCl, creatinine clearance; egfr, estimated glomerular filtration rate;, coformulated glecaprevir/pibrentasvir; HCV, hepatitis C virus; IL8B, interleukin 88; PPI, proton pump inhibitor Gane E, et al. 67th AASLD; Boston, MA; November -5, 6; Abst. LB-.

8 EXPEDITION-IV: Baseline Demographics and Clinical Characteristics Characteristic N = 4 Male, n (%) 79 (76) Black race, n (%) 6 (5) Age, median years (range) 57 (8 83) BMI, median kg/m (range) 6 (8 45) IL8B non-cc genotype, n (%) 8 (77) HCV RNA, median log IU/mL (range) 5.9 ( ) Concomitant PPI use (%) 43 (4) Characteristic, (n%) N = 4 HCV genotype a / b / other 3 () / 9 (8) / () 7 (6) 3 () 4 / 5 / 6 (9) / () / () Prior treatment history Naïve 6 (58) IFN/pegIFN ± RBV 4 (4) SOF RBV ± pegifn () Compensated cirrhosis (9) No 84 (8) CKD stage Stage 4 3 () Stage 5 9 (88) Hemodialysis 85 (8) Patients were enrolled across 9 countries: Australia, Belgium, Canada, France, Greece, Italy, New Zealand, the United Kingdom, and United States Gane E, et al. 67th AASLD; Boston, MA; November -5, 6; Abst. LB-. EXPEDITION-IV: Results SVR by Intent-To-Treat (ITT) Analysis % Patients with SVR Breakthrough Discontinuation LTFU 98 GT ITT mitt = --% SVR 4 AEs leading to study drug discontinuation One death weeks post-treatment due to cerebral hemorrhage non study drug related Gane E, et al. 67th AASLD; Boston, MA; November -5, 6; Abst. LB-.

9 EXPEDITION-IV: Post-Baseline Laboratory Abnormalities N = 4 Event, n (%) Hemoglobin Grade 3 (< g/dl) 5 (5) AST Grade (>3 x ULN) ALT Grade (>3 x ULN) Total bilirubin Grade 3 (>3 x ULN) () Grade 3 or higher laboratory abnormalities were rare Gane E, et al. 67th AASLD; Boston, MA; November -5, 6; Abst. LB-.

Felizarta, Bo Fu, Teresa Ng, Chih-Wei Lin, Federico Mensa Abstract 253. Pibrentasvir (formerly ABT-530) pangenotypic NS3/4A protease inhibitor

Felizarta, Bo Fu, Teresa Ng, Chih-Wei Lin, Federico Mensa Abstract 253. Pibrentasvir (formerly ABT-530) pangenotypic NS3/4A protease inhibitor ENDURANCE-1: A Phase 3 Evaluation of the Efficacy and Safety of 8- versus 12-week Treatment with Glecaprevir/ Pibrentasvir (formerly ABT-493/ABT-53) in HCV Genotype 1 Infected Patients with or without

More information

SURVEYOR-II Part 2 Study Design

SURVEYOR-II Part 2 Study Design HIGH SVR RATES WITH + CO-ADMINISTERED FOR 8 WEEKS IN NON-CIRRHOTIC PATIENTS WITH HCV GENOTYPE 3 INFECTION A.J. Muir, S. Strasser, S. Wang, S. Shafran, M. Bonacini, P. Kwo, D. Wyles, E. Gane, S.S. Lovell,

More information

Glecaprevir-Pibrentasvir in Non-Cirrhotic Genotype 2 ENDURANCE-2

Glecaprevir-Pibrentasvir in Non-Cirrhotic Genotype 2 ENDURANCE-2 Phase 3 Treatment Naïve or Experienced Glecaprevir-Pibrentasvir in Non-Cirrhotic Genotype 2 ENDURANCE-2 *ENDURANCE-2: Study Features ENDURANCE-2 Trial Design: Randomized, double-blind, placebo-controlled

More information

NEXT GENERATION DIRECT-ACTING ANTIVIRALS

NEXT GENERATION DIRECT-ACTING ANTIVIRALS EFFICACY AND SAFETY OF GLECAPREVIR/PIBRENTASVIR IN PATIENTS CO-INFECTED WITH HEPATITIS C VIRUS AND HUMAN IMMUNODEFICIENCY VIRUS-1: THE EXPEDITION-2 STUDY J. Rockstroh, K. Lacombe, R. Viani, C. Orkin, D.

More information

Supplementary Material

Supplementary Material Supplementary Material High Efficacy Rates of ABT-493 and ABT-530 Treatment in Patients with HCV Genotype 1 or 3 Infection and Compensated Cirrhosis Edward Gane, Fred Poordad, Stanley Wang, Armen Asatryan,

More information

Glecaprevir-Pibrentasvir in Cirrhotic Genotype 1, 2, 4, 5, and 6 EXPEDITION-1

Glecaprevir-Pibrentasvir in Cirrhotic Genotype 1, 2, 4, 5, and 6 EXPEDITION-1 Phase 3 Treatment-Naïve and Treatment-Experienced Glecaprevir-Pibrentasvir in Cirrhotic Genotype 1, 2, 4, 5, and 6 EXPEDITION-1 EXPEDITION-1: Study Features EXPEDITION-1 Trial Design: Open-label, single-arm,

More information

Glecaprevir-Pibrentasvir in HCV GT 1 or 4 & Prior DAA Treatment MAGELLAN-1 (Part 2)

Glecaprevir-Pibrentasvir in HCV GT 1 or 4 & Prior DAA Treatment MAGELLAN-1 (Part 2) Phase 3 Treatment-Experienced in HCV GT 1 or 4 & Prior DAA Treatment MAGELLAN-1 (Part 2) in HCV GT 1 or 4 & Prior DAA Treatment MAGELLAN-1 (Part 2): Study Features MAGELLAN-1 (Part 2) Trial Design: Randomized,

More information

Direct-acting Antiviral (DAA) Regimens in Late-stage Development: Which Patients Should Wait? Fred Poordad, MD

Direct-acting Antiviral (DAA) Regimens in Late-stage Development: Which Patients Should Wait? Fred Poordad, MD Direct-acting Antiviral (DAA) Regimens in Late-stage Development: Which Patients Should Wait? Fred Poordad, MD The HCV Lifecycle: Multiple Targets Polymerase Inhibitors Protease Inhibitors NS5A Inhibitors

More information

Online Supporting Information

Online Supporting Information Wyles et al Supporting Information 1 Online Supporting Information Glecaprevir/Pibrentasvir for HCV Genotype 3 Patients with Cirrhosis and Prior Treatment Experience David Wyles, Fred Poordad, Stanley

More information

HCV therapy : Clinical case

HCV therapy : Clinical case HCV therapy : Clinical case PHC 2018 Paris January 14th, 2018 Tarik Asselah (MD, PhD) Professor of Medicine Hepatology, Chief INSERM UMR 1149, Hôpital Beaujon, Clichy, France. Disclosures Professor Asselah

More information

Glecaprevir and Pibrentasvir in HCV GT 1-6 without Cirrhosis SURVEYOR-I and SURVEYOR-II

Glecaprevir and Pibrentasvir in HCV GT 1-6 without Cirrhosis SURVEYOR-I and SURVEYOR-II Phase 3 Treatment-Naïve and Treatment-Experienced Glecaprevir and Pibrentasvir in HCV GT 1-6 without Cirrhosis SURVEYOR-I and SURVEYOR-II Glecaprevir and Pibrentasvir in HCV GT 1-6 without Cirrhosis SURVEYOR-I

More information

Abstract LB-12. POLARIS-2: Pangenotypic Single Tablet Regimen with Inhibitors of HCV NS5B (Nucleotide) + NS5A + NS3

Abstract LB-12. POLARIS-2: Pangenotypic Single Tablet Regimen with Inhibitors of HCV NS5B (Nucleotide) + NS5A + NS3 A Randomized Phase 3 Trial of Sofosbuvir/Velpatasvir/Voxilaprevir for 8 Weeks Compared to Sofosbuvir/Velpatasvir for 1 Weeks in DAA-Naïve Genotype 1 6 HCV Infected Patients: The POLARIS- Study Ira M. Jacobson,

More information

Debate: Do We Need More HCV Drugs Con Standpoint

Debate: Do We Need More HCV Drugs Con Standpoint Debate: Do We Need More HCV Drugs Con Standpoint 18 th Antivirals PK Workshop, Friday 16 th June 2017, Chicago Jürgen Rockstroh Department of Medicine I University Hospital Bonn, Bonn, Germany Conflict

More information

5/12/2016. Learning Objectives. Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients

5/12/2016. Learning Objectives. Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients 5/12/216 Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients Alexander Monto, MD Professor of Clinical Medicine University of California San Francisco San Francisco,

More information

ICVH 2016 Oral Presentation: 28

ICVH 2016 Oral Presentation: 28 Ledipasvir/Sofosbuvir Is Safe and Effective for the Treatment of Patients with Genotype 1 Chronic HCV Infection in Both HCV Mono- and HIV/HCV Coinfected Patients A Luetkemeyer 1, C Cooper 2, P Kwo 3, K

More information

2.0 Synopsis. ABT-450/r, ABT-267 M Clinical Study Report R&D/17/0539. (For National Authority Use Only)

2.0 Synopsis. ABT-450/r, ABT-267 M Clinical Study Report R&D/17/0539. (For National Authority Use Only) 2.0 Synopsis AbbVie Inc. Name of Study Drug: ABT-450, ritonavir, ABT-267, ribavirin, pegylated interferon Name of Active Ingredient: ABT-450, Ritonavir, ABT-267, Ribavirin, Pegylated interferon Individual

More information

HCV Update from AASLD 2016

HCV Update from AASLD 2016 HCV Update from AASLD 2016 Ahmed Elsharkawy Consultant Hepatologist QE Birmingham Secretary and Chair-Elect of BVHG BHIVA/BVHG Feedback Meeting November 2016 Speaker Name Ahmed Elsharkawy Statement Speaking

More information

New Antivirals for Hep C in Context of HIV: Vosevi and Mavyret

New Antivirals for Hep C in Context of HIV: Vosevi and Mavyret New Antivirals for Hep C in Context of HIV: Vosevi and Mavyret John Scott, MD, MSc, FIDSA November 16, 2017 This presentation is intended for educational use only and does not in any way constitute medical

More information

Future strategies with new DAAs

Future strategies with new DAAs Future strategies with new DAAs Ola Weiland professor New direct antiviral drugs Case no 1 male with genotype 2b Male with gt 2b chronic HCV Male with gt 2b relapse afer peg-ifn + RBV during 24 weeks

More information

Case 4: A 61-year-old man with HCV genotype 3 with cirrhosis. Ira M. Jacobson, M.D. Weill Cornell Medical College New York, New York USA

Case 4: A 61-year-old man with HCV genotype 3 with cirrhosis. Ira M. Jacobson, M.D. Weill Cornell Medical College New York, New York USA Case 4: A 61-year-old man with HCV genotype 3 with cirrhosis Ira M. Jacobson, M.D. Weill Cornell Medical College New York, New York USA 1 Genotype 3 case 61-year-old man with HCV genotype 3 Cirrhosis on

More information

VII CURSO AVANCES EN INFECCIÓN VIH Y HEPATITIS VIRALES

VII CURSO AVANCES EN INFECCIÓN VIH Y HEPATITIS VIRALES VII CURSO AVANCES EN INFECCIÓN VIH Y HEPATITIS VIRALES REGIMENES TERAPÊUTICOS DE LA HEPATITIS C, INTERFERÓN FREE A Coruña 2 Febrero 2013 Rui Sarmento e Castro Centro Hospitalar do Porto HJU ECS Universidade

More information

Clinical Management: Treatment of HCV Mono-infection

Clinical Management: Treatment of HCV Mono-infection Clinical Management: Treatment of HCV Mono-infection Curtis Cooper, MD, FRCPC Associate Professor-University of Ottawa The Ottawa Hospital- Infections Diseases Viral Hepatitis Program- Director Industry

More information

Sofosbuvir-Velpatasvir-Voxilaprevir in DAA-Experienced GT 1-6 POLARIS-4

Sofosbuvir-Velpatasvir-Voxilaprevir in DAA-Experienced GT 1-6 POLARIS-4 Phase 3 Treatment Experienced Sofosbuvir-Velpatasvir-Voxilaprevir in DAA-Experienced GT 1-6 POLARIS-4 Bourlière M, et al. N Engl J Med. 217;376:2134-46. POLARIS-4: Study Features POLARIS-4 Trial Design:

More information

HCV-G3: Sofosbuvir with ledipasvir or daclatasvir?

HCV-G3: Sofosbuvir with ledipasvir or daclatasvir? HCV-G3: Sofosbuvir with ledipasvir or daclatasvir? Ioannis Goulis, MD Aristotelian University of Thessaloniki XXIII International Hepatitis B & C Meeting of Athens Hadziyannis HCV genotype 3 therapy Chronic

More information

Introduction. The ELECTRON Trial

Introduction. The ELECTRON Trial 63rd AASLD November 9-13, 12 Boston, Massachusetts Faculty Douglas T. Dieterich, MD Professor of Medicine and Director of CME Department of Medicine Director of Outpatient Hepatology Division of Liver

More information

Viva La Revolución: Options to Combat Hepatitis C

Viva La Revolución: Options to Combat Hepatitis C Viva La Revolución: Options to Combat Hepatitis C David L. Wyles, MD Professor of Medicine University of Colorado Chief, Division of Infectious Disease Denver Health Learning Objectives After attending

More information

TREATMENT OF GENOTYPE 2

TREATMENT OF GENOTYPE 2 Treatment of Genotype 2, 3,and 4 David E. Bernstein, MD, FACG Advisory Committee/Board Member: AbbVie Pharmaceuticals, Gilead, Merck, Janssen Consultant: AbbVie Pharmaceuticals, Bristol-Myers Squibb, Gilead,

More information

HCV Resistance Clinical Aspects. Sanjay Bhagani Royal Free Hospital/UCL London

HCV Resistance Clinical Aspects. Sanjay Bhagani Royal Free Hospital/UCL London HCV Resistance Clinical Aspects Sanjay Bhagani Royal Free Hospital/UCL London DAAs in 2018, and beyond % patients % patients Changing characteristics of patients treated with DAA over time Prospective,

More information

2017 Bruce Lucas Hepatology and Liver Transplant Symposium October 13th 2017 Management of Hepatitis C in Pre- and Post-Transplant Patients

2017 Bruce Lucas Hepatology and Liver Transplant Symposium October 13th 2017 Management of Hepatitis C in Pre- and Post-Transplant Patients 2017 Bruce Lucas Hepatology and Liver Transplant Symposium October 13th 2017 Management of Hepatitis C in Pre- and Post-Transplant Patients Jens Rosenau, MD Associate Professor of Medicine Acting Director

More information

Saeed Hamid, MD Alex Thompson, MD, PhD

Saeed Hamid, MD Alex Thompson, MD, PhD Saeed Hamid, MD Alex Thompson, MD, PhD 1 We will review some top line data from EASL Majority of the time discussing how the data affects daily practice 2 Grazoprevir (GZR; MK-5172) + Elbasvir (EBR; MK-

More information

Latest Treatment Updates for GT 2 and GT 3 Patients

Latest Treatment Updates for GT 2 and GT 3 Patients Latest Treatment Updates for GT 2 and GT 3 Patients Eric Lawitz, MD, AGAF, CPI Vice President, Scientific and Research Development The Texas Liver Institute Clinical Professor of Medicine University of

More information

How to optimize treatment in G3 patients? Jérôme GOURNAY, MD Hépatologie Centre Hospitalier Universitaire de Nantes France

How to optimize treatment in G3 patients? Jérôme GOURNAY, MD Hépatologie Centre Hospitalier Universitaire de Nantes France How to optimize treatment in G3 patients? Jérôme GOURNAY, MD Hépatologie Centre Hospitalier Universitaire de Nantes France Paris Hepatitis Conference, January 12, 2016 Disclosures I have received funding

More information

ONE REGIMEN, ALL GENOTYPES, 8 WEEKS

ONE REGIMEN, ALL GENOTYPES, 8 WEEKS For UK healthcare professionals only INTRODUCING MAVIRET ONE REGIMEN, ALL GENOTYPES, 8 WEEKS FOR TREATMENT-NAÏVE, NON-CIRRHOTIC PATIENTS 1 Maviret is indicated for the treatment of chronic hepatitis C

More information

Evolution of Therapy in HCV

Evolution of Therapy in HCV Hepatitis C: Update on New Therapies and AASLD 13 David Bernstein, MD, FACP, AGAF, FACP Professor of Medicine Hofstra North Shore-LIJ School of Medicine Evolution of Therapy in HCV 199 1999 1 13 (%) SVR

More information

Disclosures. Advanced HCV management. Overview. Renal failure 1/10/2018. Research Grant support to UCSF from AbbVie Gilead Merck Proteus NIH

Disclosures. Advanced HCV management. Overview. Renal failure 1/10/2018. Research Grant support to UCSF from AbbVie Gilead Merck Proteus NIH Disclosures Advanced HCV management Annie Luetkemeyer, MD Division of HIV, ID and Global Medicine ZSFG, UCSF Research Grant support to UCSF from AbbVie Gilead Merck Proteus NIH Overview Renal failure Acute

More information

Phase 3. Treatment Experienced. Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2. Afdhal N, et al. N Engl J Med. 2014;370:

Phase 3. Treatment Experienced. Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2. Afdhal N, et al. N Engl J Med. 2014;370: Phase 3 Treatment Experienced Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2 Afdhal N, et al. N Engl J Med. 2014;370:1483-93. Ledipasvir-Sofosbuvir +/- Ribavirin in Treatment-Experienced HCV

More information

Updates on the AASLD/IDSA HCV Guidance

Updates on the AASLD/IDSA HCV Guidance Updates on the AASLD/IDSA HCV Guidance Susanna Naggie, MD, MHS Associate Professor of Medicine Duke University School of Medicine Durham, North Carolina Learning Objectives After attending this presentation,

More information

Expert Perspectives: Best of HCV from EASL 2015

Expert Perspectives: Best of HCV from EASL 2015 Best of HCV from EASL 2015 Expert Perspectives: Best of HCV from EASL 2015 Saeed Hamid, MD Alex Thompson, MD, PhD This activity is supported by educational grants from AbbVie, Bristol-Myers Squibb, and

More information

Management of HCV in Prior Treatment Failure

Management of HCV in Prior Treatment Failure Management of HCV in Prior Treatment Failure Arthur Y. Kim, MD Associate Professor of Medicine Harvard Medical School Boston, Massachusetts Learning Objectives After attending this presentation, learners

More information

Hepatitis C in Special Populations

Hepatitis C in Special Populations Hepatitis C in Special Populations David E. Bernstein, MD, FACG Vice Chairman of Medicine for Clinical Trials Chief, Division of Hepatology and Sandra Atlas Bass Center for Liver Diseases Northwell Health

More information

EASL 2013 Interferon Free, All Oral Regimens for Hepatitis C. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain

EASL 2013 Interferon Free, All Oral Regimens for Hepatitis C. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain EASL 2013 Interferon Free, All Oral Regimens for Hepatitis C Maria Buti Hospital Universitario Valle Hebron Barcelona Spain The first Results with Oral therapy: a Protease Inhibitor and NS5A inhibitor

More information

Cases: Management of Hepatitis C in Prior Treatment Failure

Cases: Management of Hepatitis C in Prior Treatment Failure Cases: Management of Hepatitis C in Prior Treatment Failure David L. Wyles, MD Professor of Medicine University of Colorado Chief, Division of Infectious Disease Denver Health Learning Objectives After

More information

STATE OF THE ART Update: Treatment Options 2016 Mark Sulkowski, MD

STATE OF THE ART Update: Treatment Options 2016 Mark Sulkowski, MD Housekeeping Please turn off or silence cell phones. Restrooms are located on this floor. Make a left out of the ballroom foyer and the men s room is on your left. The ladies room is across from the elevators

More information

SYNOPSIS Final Clinical Study Report for Study AI444031

SYNOPSIS Final Clinical Study Report for Study AI444031 Name of Sponsor/Company: Bristol-Myers Squibb Name of Finished Product: Name of Active Ingredient: () Individual Study Table Referring to the Dossier (For National Authority Use Only) SYNOPSIS for Study

More information

Update on Real-World Experience With HARVONI

Update on Real-World Experience With HARVONI Update on Real-World Experience With A RESOURCE FOR PAYERS This information is intended for payers only. The HCV-TARGET and TRIO studies were supported by Gilead Sciences, Inc. Real-world experience data

More information

Genotype 1 HCV in 2016: Clinical Decision Making in a Time of Plenty

Genotype 1 HCV in 2016: Clinical Decision Making in a Time of Plenty Genotype 1 HCV in 216: Clinical Decision Making in a Time of Plenty Ira M. Jacobson, MD Chair, Department of Medicine Mount Sinai Beth Israel Senior Faculty and Vice-Chair, Department of Medicine Icahn

More information

Emerging Therapies for HCV: Highlights from AASLD 2012 (Part 1)

Emerging Therapies for HCV: Highlights from AASLD 2012 (Part 1) Emerging Therapies for HCV: Highlights from AASLD 2012 (Part 1) Goals for Hepatitis C Therapy Compared to PegIFN/RBV, new products should offer: Improved efficacy Efficacy in all patient types including

More information

ABT-493/ABT-530 M Clinical Study Report Post-Treatment Week 12 Primary Data R&D/16/0145. Referring to Part of Dossier: Volume: Page:

ABT-493/ABT-530 M Clinical Study Report Post-Treatment Week 12 Primary Data R&D/16/0145. Referring to Part of Dossier: Volume: Page: 2.0 Synopsis AbbVie Inc. Name of Study Drug: ABT-493/ABT-530 Name of Active Ingredient: ABT-493: (3aR,7S,10S,12R,21E,24aR)- 7-tert-butyl-N-{(1R,2R)-2- (difluoromethyl)-1-[(1- methylcyclopropane-1- sulfonyl)carbamoyl]cyclopropyl}-20,20-

More information

HCV: The next 18 months. David L. Wyles, M.D. Associate Professor of Medicine UCSD

HCV: The next 18 months. David L. Wyles, M.D. Associate Professor of Medicine UCSD HCV: The next 18 months David L. Wyles, M.D. Associate Professor of Medicine UCSD FIRST, A LOOK BACK WHAT DID I SAY LAST YEAR? My predictions for genotype 1: Multiple highly efficacious, well-tolerated,

More information

Ledipasvir-Sofosbuvir (Harvoni)

Ledipasvir-Sofosbuvir (Harvoni) HEPATITIS WEB STUDY HEPATITIS C ONLINE Ledipasvir-Sofosbuvir (Harvoni) Robert G. Gish MD Professor, Consultant, Stanford University Medical Center Senior Medical Director, St Josephs Hospital and Medical

More information

ABT-493, ABT-530, ABT-493/ABT-530 M Clinical Study Report Primary Analysis R&D/16/0160. Referring to Part of Dossier: Volume: Page:

ABT-493, ABT-530, ABT-493/ABT-530 M Clinical Study Report Primary Analysis R&D/16/0160. Referring to Part of Dossier: Volume: Page: 2.0 Synopsis AbbVie Inc. Name of Study Drug: ABT-493, ABT-530, ABT-493/ABT-530 Name of Active Ingredient: ABT-493: (3aR,7S,10S,12R,21E,24aR)- 7-tert-butyl-N-{(1R,2R)-2- (difluoromethyl)-1-[(1- methylcyclopropane-1-

More information

New developments in HCV research and their implications for front-line practice

New developments in HCV research and their implications for front-line practice New developments in HCV research and their implications for front-line practice Dr. Curtis Cooper Associate Professor, University of Ottawa Director, Ottawa Hospital Viral Hepatitis Program June 17, 2013

More information

ABT-493/ABT-530 M Clinical Study Report Post-Treatment Week 12 Primary Data R&D/16/0144. Referring to Part of Dossier: Volume: Page:

ABT-493/ABT-530 M Clinical Study Report Post-Treatment Week 12 Primary Data R&D/16/0144. Referring to Part of Dossier: Volume: Page: 2.0 Synopsis AbbVie Inc. Name of Study Drug: ABT-493/ABT-530 Name of Active Ingredient: ABT-493: (3aR,7S,10S,12R,21E,24aR)- 7-tert-butyl-N-{(1R,2R)-2- (difluoromethyl)-1-[(1- methylcyclopropane-1- sulfonyl)carbamoyl]cyclopropyl}-20,20-

More information

ABT-493/ABT-530 M Clinical Study Report Post-Treatment Week 12 Primary Data R&D/16/0162. Referring to Part of Dossier: Volume: Page:

ABT-493/ABT-530 M Clinical Study Report Post-Treatment Week 12 Primary Data R&D/16/0162. Referring to Part of Dossier: Volume: Page: 2.0 Synopsis AbbVie Inc. Name of Study Drug: ABT-493/ABT-530 Name of Active Ingredient: ABT-493: (3aR,7S,10S,12R,21E,24aR)- 7-tert-butyl-N-{(1R,2R)-2- (difluoromethyl)-1-[(1- methylcyclopropane-1- sulfonyl)carbamoyl]cyclopropyl}-20,20-

More information

SOLAR-1 (Cohorts A and B)

SOLAR-1 (Cohorts A and B) Phase 2 Treatment Naïve and Treatment Experienced Ledipasvir-Sofosbuvir + RBV in HCV GT 1,4 and Advanced Liver Disease SOLAR-1 (Cohorts A and B) Charlton M, al. Gastroenterology. 2015; 149:649-59. Ledipasvir-Sofosbuvir

More information

Treatment of HCV in 2016

Treatment of HCV in 2016 5/1/16 Treatment of HCV in 16 Graham R Foster Professor of Hepatology QMUL Conflicts of Interest Speaker and consultancy fees received from AbbVie, BI, BMS, Gilead, Janssen, Roche, Merck, Novartis, Springbank,

More information

Case 2: A 71-year-old man with cirrhosis

Case 2: A 71-year-old man with cirrhosis Case 2: A 71-year-old man with cirrhosis 1 JM, 71 year old African American male with known cirrhosis Asymptomatic apart from fatigue No prior history of decompensation Past history: Diabetes for 11 years

More information

Treatment of HCV : 100 % cure?

Treatment of HCV : 100 % cure? Treatment of HCV : % cure? PHC 8 PARIS January 5th, 8 Tarik Asselah (MD, PhD) Professor of Medicine Hepatology, Chief ISERM UMR 49, Hôpital Beaujon, Clichy, France. PHC 8 - www.aphc.info Disclosures Employee

More information

VIRAL LIVER DISEASE. OAG Post DDW Course Westin Prince, Toronto, June 13-14, 2015

VIRAL LIVER DISEASE. OAG Post DDW Course Westin Prince, Toronto, June 13-14, 2015 VIRAL LIVER DISEASE OAG Post DDW Course Westin Prince, Toronto, June 13-14, 2015 Financial Interest Disclosure (over the past 24 months) Dr. Paul Marotta Relationships related to this presentation! Research

More information

Update in the Management of Hepatitis C: What Does the Future Hold

Update in the Management of Hepatitis C: What Does the Future Hold Update in the Management of Hepatitis C: What Does the Future Hold Paul Y Kwo, MD, FACG Professor of Medicine Mdi Medical ldirector, Liver Transplantation tti Gastroenterology/Hepatology Division Indiana

More information

DRUG-DRUG INTERACTIONS OF GLECAPREVIR AND PIBRENTASVIR WITH PRAVASTATIN, ROSUVASTATIN, OR DABIGATRAN ETEXILATE

DRUG-DRUG INTERACTIONS OF GLECAPREVIR AND PIBRENTASVIR WITH PRAVASTATIN, ROSUVASTATIN, OR DABIGATRAN ETEXILATE DRUG-DRUG INTERACTIONS OF GLECAPREVIR AND PIBRENTASVIR WITH PRAVASTATIN, ROSUVASTATIN, OR DABIGATRAN ETEXILATE Matthew P. Kosloski, Weihan Zhao, Hong Li, Stanley Subhead Wang, Calibri Joaquin 14pt, Valdes,

More information

NS5A inhibitors: ideal candidates for combination?

NS5A inhibitors: ideal candidates for combination? NS5A inhibitors: ideal candidates for combination? Professor Vasily Isakov, MD, PhD, AGAF Dep.Gastroentrology & Hepatology, ION, Russian Academy of Sciences, Moscow Structure and function of NS5A Meigang

More information

Associate Professor of Medicine University of Chicago

Associate Professor of Medicine University of Chicago Nancy Reau, MD Associate Professor of Medicine University of Chicago Management of Hepatitis C: New Drugs and New Paradigms HCV is More Lethal than HIV Infection HCV superseded HIV as a cause of death

More information

Treating HCV Genotype 2 & 3

Treating HCV Genotype 2 & 3 Treating HCV Genotype 2 & 3 3rd Workshop on HCV Therapy Advances, Rome 14.12.2013 Christoph Sarrazin Klinikum der J. W. Goethe-Universität Frankfurt am Main, Germany HCV Genotypes 2 & 3 Laurel and Hardy

More information

HCV in 2017: New Therapies and New Opportunities. Presentation prepared by: Date prepared: OBJECTIVES

HCV in 2017: New Therapies and New Opportunities. Presentation prepared by: Date prepared: OBJECTIVES Project ECHO HCV Collaborative HCV in 217: New Therapies and New Opportunities Paulina Deming, PharmD Assistant Director Hepatitis C Programs, ECHO Institute Associate Professor College of Pharmacy University

More information

Hepatitis C: New Therapies in

Hepatitis C: New Therapies in Hepatitis C: New Therapies in 216-217 Mark Sulkowski, MD Professor of Medicine Johns Hopkins University School of Medicine Medical Director, Viral Hepatitis Center Divisions of Infectious Diseases and

More information

HCV Treatment Options in 2017/2018: What s Here and What s Coming Soon

HCV Treatment Options in 2017/2018: What s Here and What s Coming Soon HCV Treatment Options in 2017/2018: What s Here and What s Coming Soon Supported by educational grants from AbbVie; Bristol-Myers Squibb; Gilead Sciences; Janssen Therapeutics; Merck & Co., Inc; and ViiV

More information

SVR Updates from the 2013 EASL

SVR Updates from the 2013 EASL Updates from the 2013 EASL By Tracy Swan, Treatment Action Group Streamlining HCV Treatment Treatment for hepatitis C virus (HCV) is becoming simpler, shorter, and more effective. All-oral combinations

More information

Antiviral treatment in HCV cirrhotic patients on waiting list

Antiviral treatment in HCV cirrhotic patients on waiting list Antiviral treatment in HCV cirrhotic patients on waiting list Krzysztof Tomasiewicz Department of Hepatology and Infectious Diseases Medical University of Lublin, Poland Disclosures Consultancy/Advisory

More information

C-CREST study, Part A: GZR + EBR or MK MK-3682 for genotypes 1, 2 and 3 - Phase II

C-CREST study, Part A: GZR + EBR or MK MK-3682 for genotypes 1, 2 and 3 - Phase II Design 18 years Chronic HCV infection Genotype 1, 2 or 3 Treatment-naïve HCV RNA 1 IU/ml No cirrhosis * No HBV or HIV co-infection Randomisation Open-label * Liver biopsy or Fibroscan 12.5 kpa or Fibrotest

More information

Treatement Experienced patients without cirrhosis. Rafael Esteban Hospital Universitario Valle Hebron Barcelona

Treatement Experienced patients without cirrhosis. Rafael Esteban Hospital Universitario Valle Hebron Barcelona Treatement Experienced patients without cirrhosis Rafael Esteban Hospital Universitario Valle Hebron Barcelona Agenda With IFN PegIFN+ Ribavirin + Simeprevir PegIFN+ Ribavirin+ Sofosbuvir Without IFN Sofosbuvir

More information

Australasian Professional Society on Alcohol and other Drugs, Annual Conference 2016 Sydney Australia

Australasian Professional Society on Alcohol and other Drugs, Annual Conference 2016 Sydney Australia Efficacy and safety of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic HCV genotype 1 infection receiving opioid substitution therapy: Analysis of Phase 3 ION trials J Grebely

More information

What Should We Do With Difficult to Treat HCV Populations?

What Should We Do With Difficult to Treat HCV Populations? What Should We Do With Difficult to Treat HCV Populations? Norah Terrault, MD Professor of Medicine and Surgery Director, Viral Hepatitis Center University of California San Francisco Disclosures Norah

More information

Update on Hepatitis C. Francesco Negro Hôpitaux Universitaires de Genève Berne, November 15, 2017

Update on Hepatitis C. Francesco Negro Hôpitaux Universitaires de Genève Berne, November 15, 2017 Update on Hepatitis C Francesco Negro Hôpitaux Universitaires de Genève Berne, November 15, 2017 The global prevalence of HCV was 1 0% (95% uncertainty interval 0 8 1 1) in 2015: 71 1 million (62 5 79

More information

47 th Annual Meeting AISF

47 th Annual Meeting AISF 47 th Annual Meeting AISF Rome, 21 February 2014 Present and future treatment strategies for patients with HCV infection: chronic hepatitis and special populations (HCV/HIV coinfection, advanced cirrhosis,

More information

Update on Real-World Experience With HARVONI

Update on Real-World Experience With HARVONI Update on Real-World Experience With A RESOURCE FOR PAYERS MAY 217 This information is intended for payers only. The HCV-TARGET study was supported by Gilead Sciences, Inc. Real-world experience data were

More information

Learning Objective. After completing this educational activity, participants should be able to:

Learning Objective. After completing this educational activity, participants should be able to: Learning Objective After completing this educational activity, participants should be able to: Use patient characteristics and preferences to select HCV treatment strategies that maximize the potential

More information

Kristen M. Marks, MD Assistant Professor Weill Cornell Medical College New York, New York

Kristen M. Marks, MD Assistant Professor Weill Cornell Medical College New York, New York Newly Approved Hepatitis C Virus Drugs: Approach to Initial Therapy Kristen M. Marks, MD Assistant Professor Weill Cornell Medical College New York, New York Learning Objectives After attending this presentation,

More information

Hepatitis C Agents

Hepatitis C Agents Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.41 Subject: Hepatitis C Agents Page: 1 of 20 Last Review Date: March 16, 2018 Hepatitis C Agents Description

More information

Hepatitis C Agents

Hepatitis C Agents Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.41 Subject: Hepatitis C Agents Page: 1 of 19 Last Review Date: December 8, 2017 Hepatitis C Agents

More information

Hepatitis C Genotypes

Hepatitis C Genotypes 9/2/21 OBJECTIVES Project ECHO HCV Collaborative HCV in 21: New Therapies and New Opportunities Paulina Deming, PharmD Assistant Director Hepatitis C Programs, ECHO Institute Associate Professor College

More information

Initial Treatment of HCV G Hugo E. Vargas, MD Professor of Medicine Medical, Director Office of Clinical Research Mayo Clinic Arizona

Initial Treatment of HCV G Hugo E. Vargas, MD Professor of Medicine Medical, Director Office of Clinical Research Mayo Clinic Arizona Initial Treatment of HCV G1 2016 Hugo E. Vargas, MD Professor of Medicine Medical, Director Office of Clinical Research Mayo Clinic Arizona Disclosure Information Disclosure Information Dr. Vargas receives

More information

Hepatitis C Update: What s New in 2017

Hepatitis C Update: What s New in 2017 Hepatitis C Update: What s New in 2017 Cody A. Chastain, MD Assistant Professor of Medicine Viral Hepatitis Program Division of Infectious Diseases Vanderbilt University Medical Center Cody.a.Chastain@Vanderbilt.edu

More information

10/4/2016. Management of Hepatitis C Virus Genotype 2 or 3 Infection

10/4/2016. Management of Hepatitis C Virus Genotype 2 or 3 Infection Management of Hepatitis C Virus Genotype 2 or 3 Infection Kenneth E. Sherman, MD, PHD Gould Professor of Medicine Director, Division of Digestive Diseases University of Cincinnati Cincinnati, Ohio FORMATTED:

More information

Emerging Therapies for HCV: Highlights from AASLD 2012 (Part 2)

Emerging Therapies for HCV: Highlights from AASLD 2012 (Part 2) Emerging Therapies for HCV: Highlights from AASLD 2012 (Part 2) Goals for Hepatitis C Therapy Compared to PegIFN α/rbv, new treatment regimens for chronic hepatitis C should offer: Improved efficacy Efficacy

More information

Hepatitis C: Management of Treatment Naïve Patients with First Line Protease Inhibitors

Hepatitis C: Management of Treatment Naïve Patients with First Line Protease Inhibitors Hepatitis C: Management of Treatment Naïve Patients with First Line Protease Inhibitors Eric Lawitz, MD, AGAF, CPI The Texas Liver Institute Clinical Professor of Medicine University of Texas Health Science

More information

Clinical Сase A previously relapse to PEG IFN + RBV in HCV G3a patient. Konstantin Zhdanov

Clinical Сase A previously relapse to PEG IFN + RBV in HCV G3a patient. Konstantin Zhdanov Clinical Сase A previously relapse to PEG IFN + RBV in HCV G3a patient Konstantin Zhdanov Genotype 3 in Europe Canada Norway Germany Sweden Czech Republic Poland Approximately 1/3 of HCV-infected patients

More information

Why make this statement?

Why make this statement? HCV Council 2014 10 clinical practice statements were evaluated by the Council A review of the available literature was conducted The level of support and level of evidence for the statements were discussed

More information

Ombitasvir-Paritaprevir-Ritonavir + Dasabuvir (Viekira Pak)

Ombitasvir-Paritaprevir-Ritonavir + Dasabuvir (Viekira Pak) HEPATITIS WEB STUDY HEPATITIS C ONLINE Ombitasvir-Paritaprevir-Ritonavir + Dasabuvir (Viekira Pak) Prepared by: Sophie Woolston, MD and David H. Spach, MD Last Updated: December 29, 2014 OMBITASVIR-PARITAPREVIR-RITONAVIR

More information

Hepatitis C: Management of Previous Non-responders with First Line Protease Inhibitors

Hepatitis C: Management of Previous Non-responders with First Line Protease Inhibitors Hepatitis C: Management of Previous Non-responders with First Line Protease Inhibitors Fred Poordad, MD The Texas Liver Institute Clinical Professor of Medicine University of Texas Health Science Center

More information

Update on the Treatment of HCV

Update on the Treatment of HCV Update on the Treatment of HCV K. Rajender Reddy, MD Professor of Medicine Director of Hepatology Director, Viral Hepatitis Center University of Pennsylvania Philadelphia, USA 1 K. Rajender Reddy, MD Disclosure

More information

The ASTRAL Program Abstracts LB-2, LB-12, 205, 209

The ASTRAL Program Abstracts LB-2, LB-12, 205, 209 The ASTRAL Program Abstracts LB-2, LB-12, 5, 9 The ASTRAL Program FDC 1. 2. 3. 4. 5. SOF Nucleotide polymerase inhibitor VEL NS5A inhibitor ASTRAL1 GT1, 2, 4 6 ASTRAL2 GT2 Jacobson IM, et al. N Engl J

More information

Dr. Siddharth Srivastava

Dr. Siddharth Srivastava Dr. Siddharth Srivastava MD, DM (Gastroenterology) Associate Professor GIPMER, New Delhi Rashtriya Gaurav Award 2013 for work on hepatitis B and C Set up Liver clinic at GIPMER and in charge EUS laboratory.

More information

Treatment of Unique Populations Raymond T. Chung, MD

Treatment of Unique Populations Raymond T. Chung, MD Treatment of Unique Populations Raymond T. Chung, MD Director of Hepatology and Liver Center Vice Chief, Gastroenterology Kevin and Polly Maroni Research Scholar Mass General Hospital Disclosures Research

More information

Do We Need New HCV Drugs? YES

Do We Need New HCV Drugs? YES Do We Need New HCV Drugs? YES Nancy Reau, MD Professor of Medicine Chief, Section of Hepatology Associate Director, Solid Organ Transplantation Rush University Medical Center Disclosures Consultation:

More information

What is the Optimized Treatment Duration? To Overtreat versus Undertreat. Nancy Reau, MD Associate Professor of Medicine University of Chicago

What is the Optimized Treatment Duration? To Overtreat versus Undertreat. Nancy Reau, MD Associate Professor of Medicine University of Chicago What is the Optimized Treatment Duration? To Overtreat versus Undertreat Nancy Reau, MD Associate Professor of Medicine University of Chicago Learning Objectives: 1. Discuss patient populations appropriate

More information

Hepatitis C Emerging Treatment Paradigms

Hepatitis C Emerging Treatment Paradigms Hepatitis C Emerging Treatment Paradigms David R Nelson MD Assistant Vice President for Research Professor of Medicine Director, Clinical and Translational Science Institute University of Florida Gainesville,

More information

Treatments of Genotype 2, 3,and 4: Now and in the future

Treatments of Genotype 2, 3,and 4: Now and in the future Treatments of Genotype 2, 3,and 4: Now and in the future THERAPY FOR THE TREATMENT OF GENOTYPE 2 1 GT 2 and GT 3 Treatment-Naïve: SOF+RBV vs PEG-IFN+RBV FISSION Study Design HCV GT 2 and GT 3 Treatment-naïve

More information

Hepatitis C Treatment 2014

Hepatitis C Treatment 2014 Hepatitis C Treatment 214 Brendan M. McGuire, MD UAB Liver Center Outline Epidemiology/National History Terminology for Treatment Treatment Considerations Current Treatment Options Genotype 1 (GT 1) Genotype

More information